We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.
Partnerships MTEC/DoW award of $28.7M non-dilutive funding (partially funding diSArm study, EOP2, Phase 3 readiness)
Indications
Complicated S. aureus bacteremia (SAB)(Phase 3)
Prosthetic joint infection / wound infections (S. aureus)(Stage not disclosed)
Catalysts
— 2H 2026
Status note End-of-Phase 2 meeting completed; FDA agreed Phase 2a diSArm data support advancement to Phase 3 superiority study; Fast Track designation granted May 5, 2026; complete Phase 3 protocol submitted to FDA; Phase 3 start anticipated 2H 2026. PJI/wound Phase 1b/2a not yet initiated, conditional on funding.
Acute pneumonia (incl. ventilator-associated pneumonia) from P. aeruginosa(Preclinical)
Status note Novel phage cocktail identified for acute bacterial pneumonia; IND filing contingent on securing sufficient funding.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.